Research and Reports in Urology (May 2023)
PCA3 and TMPRSS2: ERG Urine Level as Diagnostic Biomarker of Prostate Cancer
Abstract
Syah Mirsya Warli,1,2 Muhammad Haritsyah Warli,3 Fauriski Febrian Prapiska2 1Department of Urology, Faculty of Medicine Universitas Sumatera Utara – Universitas Sumatera Utara Hospital, Medan, North Sumatera, Indonesia; 2Department of Surgery Urology Division, Faculty of Medicine Universitas Sumatera Utara – Haji Adam Malik General Hospital, Medan, North Sumatera, Indonesia; 3Department of Urology, Faculty of Medicine Universitas Indonesia – Haji Adam Malik General Hospital, Medan, North Sumatera, IndonesiaCorrespondence: Syah Mirsya Warli, Tel +62 61-8364930, Email [email protected]: Prostate cancer is a highly prevalent urological carcinoma with an increasing incidence in Indonesia and all around the world. Early diagnosis can greatly affect treatment outcomes and increase life expectancy. Several biomarkers for detecting prostate cancer have been studied and showed great promise.Purpose: This study aims to analyze prostate cancer antigen 3 (PCA3) as well as transmembrane serine protease 2:ERG (TMPRSS2:ERG) for diagnosing and serving as urine biomarkers in predicting prostate cancer incidences.Methods: We conducted an analytical study to assess the utility of PCA3 and TMPRSS2:ERG for detecting prostate cancer. Thirty samples were included in this study to see the utilization of PCA3 and TMPRSS2:ERG as diagnostic biomarkers of prostate cancer. A urine sample was taken and the PCA3 test was performed using the PCA3 PROGENSA test, while the TMPRSS2:ERG was performed using the chemiluminescent DNA probe method with a hybridization protection test.Results: The average age of the subject was 61.07± 8.3 years. Based on calculations using the Mann–Whitney test, there was a significant relationship between prostate-Specific Antigen (PSA) overexpression (p< 0.001), TMPRSS2:ERG (p=0.001), and PCA3 (p=0.003) with prostate cancer incidence. The sensitivity of PCA3 and TMPRSS2:ERG in detecting prostate cancer was 76.9% and 92.3%, respectively. Hence, TMPRSS2:ERG and PCA3 can be used as biomarkers for the occurrence of prostate cancer. We also performed a Kruskal–Wallis test; however, there was no significant relationship between PSA (p=0.236), TMPRSS2:ERG (p=0.801), and PCA3 (p=0.091) with the Gleason score.Conclusion: There is a significant correlation between overexpression of PSA, TMPRSS2:ERG and PCA3 with the incidence of prostate cancer, and TMPRSS2:ERG and PCA3 can be used as biomarkers of prostate cancer.Keywords: prostate cancer, PSA, PCA3, TMPRSS2:ERG, urine biomarker
